Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Finished Goods (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Finished Goods for 7 consecutive years, with $430000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods fell 9.85% year-over-year to $430000.0, compared with a TTM value of $430000.0 through Dec 2025, down 9.85%, and an annual FY2025 reading of $430000.0, down 9.85% over the prior year.
  • Finished Goods was $430000.0 for Q4 2025 at Karyopharm Therapeutics, down from $433000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $991000.0 in Q3 2022 and bottomed at $114000.0 in Q1 2021.
  • Average Finished Goods over 5 years is $547600.0, with a median of $455000.0 recorded in 2024.
  • The sharpest move saw Finished Goods surged 424.05% in 2021, then crashed 44.02% in 2025.
  • Year by year, Finished Goods stood at $414000.0 in 2021, then surged by 135.75% to $976000.0 in 2022, then dropped by 22.34% to $758000.0 in 2023, then plummeted by 37.07% to $477000.0 in 2024, then dropped by 9.85% to $430000.0 in 2025.
  • Business Quant data shows Finished Goods for KPTI at $430000.0 in Q4 2025, $433000.0 in Q3 2025, and $349000.0 in Q2 2025.